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Abstract
The conduct of Phase I/II HIV vaccine trials internationally necessitates the development of region-specific clinical reference
ranges for trial enrolment and participant monitoring. A population based cohort of adults in Kericho, Kenya, a potential
vaccine trial site, allowed development of clinical laboratory reference ranges. Lymphocyte immunophenotyping was
performed on 1293 HIV seronegative study participants. Hematology and clinical chemistry were performed on up to 1541
cohort enrollees. The ratio of males to females was 1.9:1. Means, medians and 95% reference ranges were calculated and
compared with those from other nations. The median CD4+ T cell count for the group was 810 cells/ml. There were
significant gender differences for both red and white blood cell parameters. Kenyan subjects had lower median hemoglobin
concentrations (9.5 g/dL; range 6.7–11.1) and neutrophil counts (1850 cells/ml; range 914–4715) compared to North
Americans. Kenyan clinical chemistry reference ranges were comparable to those from the USA, with the exception of the
upper limits for bilirubin and blood urea nitrogen, which were 2.3-fold higher and 1.5-fold lower, respectively. This study is
the first to assess clinical reference ranges for a highland community in Kenya and highlights the need to define clinical
laboratory ranges from the national community not only for clinical research but also care and treatment.
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Introduction
Many human immunodeficiency virus (HIV-1) vaccine trials are
slated for Phase I–III trials in Africa[1].The inception of the US
President’s Emergency Plan for AIDS Relief in 2004[2], with a
mandate to treat 2 million HIV infections with anti-retroviral
therapy (ART) by 2008 has accelerated the implementation of
lymphocyte immunophenotyping in urban and rural areas in
Africa as initiation of therapy is often predicated by absolute
CD4+ T- lymphocyte counts. Central to any HIV vaccine and/or
care and treatment program is the capability to measure absolute
CD4 counts. CD4 counts are important in the context of
breakthrough infections during HIV vaccine trials and informing
treatment.
Phase I/II vaccine trials rely on the clinical laboratory for
assessing safety, with particular emphasis on assays monitoring
hematology, liver and kidney function. In addition, the treatment
of HIV infection requires monitoring of drug toxicity on renal,
hepatic and hematologic parameters. The majority of immuno-
hematological and clinical chemistry reference ranges are based on
North American or European data. Recently, there has been an
increased initiative to determine immunohematologic reference
ranges in Asia and Africa [3,4,5,6,7,8,9,10,11,12,13,14,15,16].
Several factors including genetics, dietary patterns, sex, age and
altitude can affect immunohematology and clinical chemistry
reference ranges [17,18]. Immunophenotyping of lymphocyte
subsets has shown marked differences in CD4 T-cell counts
depending on ethnicity. Lower CD4 T-cell numbers have been
reported in Asians and Ethiopians compared to Caucasians
[6,11,19], although absolute CD4 T cell counts in Africans from
the Central African Republic have been reported to be similar to
Europeans [10].
As early as 1941, hematology reference ranges were found to
differ by race [20]. A study among four ethnic groups in the
United Kingdom reported that black women had significantly
lower white cell and neutrophil counts compared to Indian,
Northern European and Oriental women [21]. Reference ranges
for clinical chemistry, while well documented in North America
[22], appear to have been little addressed in less industrialized
countries. A reference range study for serum alanine aminotrans-
ferase (ALT) was conducted among Iranian blood donors and
reported gender differences [23]. With the exception of a recent
report by Saathoff et al., there are no published clinical chemistry
reference range data for Africa [24]. The conduct of many Phase
I/II HIV vaccine trials in Africa and Asia (http://www.iavireport.
org/trialsdb/), and the increased global use of ART [25,26,27]
support the need for national or regional reference ranges.
In addition to the need for local clinical reference ranges to
successfully conduct HIV care and interpret data from HIV
vaccine trials, these data guide clinical decision making for other
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national HIV vaccine trial in Kericho, Kenya, Mbeya, Tanzania
and Kampala, Uganda. Prior to the execution of the vaccine trial
in Kenya, there was an ongoing study to define the prevalence and
incidence of HIV-1 infection in Kericho [28]. This allowed the
opportunity to collect clinical laboratory reference ranges from this
rural community. This report describes the collection and
determination of reference ranges for a rural high-altitude
population in Kenya.
Methods
Subjects
Study participants aged from 18 to 55 years were enrolled in a
natural history cohort evaluating HIV-1 infection on a tea
plantation in Kericho, Kenya [28,29]. The predominant tribes
in the cohort were Kalenjin, Kisii, Luo and Luhya [28]. Kericho is
approximately 2042 m above sea level and lies 260 km northwest
of Nairobi. Medical staff performed physical examinations and
collected clinical histories. Participants who were not febrile,
pregnant, HIV seropositive, and did not screen positive for syphilis
and malaria were entered into the reference range sub-study.
Values for 122 subjects were excluded from the analysis. No
significant differences between this group and that included in the
analyses were detected by either gender or age.
Reference value data were collected at study entry from 1,293
subjects: 848 (66%) males and 445 females from July to December
2003 for lymphocyte immunophenotyping. Reference values for
clinical chemistry and hematology were collected from July to
December 2004 from up to 1,541 individuals–1020 (66%) men
and 521 women.
HIV and Syphilis Serology
Serum samples were tested as described previously [30]. Briefly
sera were initially screened for HIV antibodies using Genetic
Systems rLAV EIA (BioRad Laboratories, Redmond, WA, USA).
Reactive samples were tested in duplicate with the Vironostika
HIV-1 Microelisa Systems (Organon Teknika, Durham, NC,
USA) and repeatedly reactive samples confirmed with Genetic
Systems HIV-1 Western blot (Bio-Rad Laboratories). Syphilis
testing was performed using the Wampole Laboratories Impact
RPR (Wampole Laboratories, Princeton, NJ, USA). Both the HIV
and syphilis tests were approved by the US Food and Drug
Administration (FDA).
Malaria Testing
Thick film blood smears were prepared and read blinded by two
independent readers. Discrepant results were resolved by a third
reader. If the thick film was positive for parasites, thin films were
prepared and parasites enumerated. A face-to-face questionnaire
was also administered to each study participant to obtain a history
of ever having had malaria infection and/or symptoms within the
previous 6 months.
Immunophenotyping
Blood was collected into a 7 ml Vacutainer tube containing
EDTA (Becton Dickinson, Franklin Lakes, N.J., USA). Determi-
nation of lymphocyte subsets was performed using a FACSCalibur
flow cytometer (Becton Dickinson Immunocytometry Systems,
San Jose, CA, USA) and single platform technology. Two
combinations of 4 monoclonal antibodies were used (anti-CD3/
CD8/CD45/CD4 and anti-CD3/CD16+56/CD45/CD19) and
TruCOUNT tubes (Becton Dickinson). Blood was stored at 20–
25uC, stained within 48 h of collection and analyzed within 24 h
of staining. Lymphocyte subsets were enumerated using MultiSET
software (Becton Dickinson). Samples from 100 participants were
excluded from the analysis due to the results failing our assay
quality control criteria of the lymphocyte subset sum being outside
of the 95%–105% range and/or the difference between replicate
CD3 results being greater than 2%.
Hematology
A complete blood count (CBC) and differential was performed on
the identical blood sample used for immunophenotyping using an
ACT 5Diff CP instrument (Beckman Coulter, Fullerton, CA, USA)
within 24 h of specimen collection in accordance with manufactur-
er’s instructions. The machine automatically dilutes a whole-blood
sample of 45 ml in the CBC/Differential mode, lyses and counts.
Clinical Chemistry
Samples for serum chemistry were collected in 3 ml serum tubes
(Becton Dickinson). Serum was separated within 4 h of collection
and analyzed within 12 h of blood draw using the Roche Cobas
Integra 400 Chemistry Analyzer (Roche Diagnostics, Mannheim,
Germany) for all analytes according to the manufacturer’s
instructions. Data from 22 subjects were totally excluded from
the analysis due to one or more analyte result being clinically
implausible.
Quality Control
In addition to commercial controls run daily with each of the
three instruments, the laboratory routinely participates (3 times
per year) in external proficiency testing panels distributed by the
College of American Pathologists for lymphocyte immunopehno-
typing, hematology and clinical chemistry, and the United
Kingdom National External Quality Assurance Service for
lymphocyte typing. In the event that the daily commercial controls
failed, testing was suspended.
Ethics
Institutional Review Boards in the United States and Kenya
approved the study. Written informed consent was obtained from
each participant prior to blood collection.
Statistical Analysis
All calculations for determining reference ranges were based on
the guidelines found in the Clinical and Laboratory Standards
Institute (CLSI: formerly National Council of Clinical Laboratory
Services) guideline document C28-A2 [17]. Overall and gender-
stratified data by analyte were evaluated for a normal distribution
using the Shapiro-Wilks test, the Kolmogorov-Smirnov test with
Lilliefors correction and the D’Agostino-Pearson test, and with
diagnostic plots (i.e., boxplots and normal probability Q-Q plots).
When the values of these tests were not statistically significant, we
assumed that the distribution was Gaussian, and the 2.5% and
97.5% reference intervals were estimated using the mean and two
standard deviations (S.D.). In the event of a non-Gaussian
distribution, data were transformed (i.e., log-linear, the square
root and inverse) to achieve normality, the mean and two S.D.
were estimated and the data back-transformed to the original
units. When normality could not be achieved, a non-parametric
method was applied, which consists of ordering the data and
estimating the sample 2.5 and 97.5 percentile to form the 95%
reference intervals. Differences between genders were evaluated
using the Student-t test or the Mann-Whitney U test. All statistical
analyses were carried out using Stata v.9.0 (Stata Corporation,
College Station, TX).
Reference Ranges for Kenya
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The mean age of all participants at study entry was 30 years.
Men were marginally older than women, with mean ages of 31
years and 30 years, respectively. The frequency of malaria
confirmed by blood film microscopy at baseline was 3%. Table 1
shows the median and 95
th percentile reference ranges for
lymphocyte subsets for all 1293 eligible participants stratified by
gender. Lymphocyte subset absolute numbers, with the exception
of natural killer (NK) cells, were significantly different (P,0.05)
between males and females, with women showing higher numbers
for most subsets, with the exception of CD8+ T cell % and NK cell
%. All study participants had a CD4 count of greater than
400 cells/ml, with 15% of men and 47% of women having a CD4
cell count exceeding 1000 cells/ml. The mean CD4 cell counts for
men and women were 771 cells/ml and 1002 cells/ml, respectively,
with an overall mean of 851 cells/ml.
Table 2 shows selected hematology reference ranges for the
Kericho cohort. There was a statistically significant difference
(P,0.05) in all hematology parameters between men and women,
with the former showing higher red blood cell counts, hemoglobin
concentration and hematocrit levels compared to females.
However women had higher white blood cell and platelet counts
compared to men.
Clinical chemistry values for the Kericho cohort are shown in
Table 3. The full range of analytes was not run for all subjects,
primarily due to insufficient test kits for that analyte, or in rare cases,
failure ofthe commercialqualitycontrolmaterials.Except forsodium
and glucose, all parameters were significantly different between
genders, with higher median values in men for most analytes (12/17).
Comparing the reference ranges for hepatic and renal function shows
that males had elevated liver enzymes and creatinine levels compared
to females, but these were not clinically significant.
Comparing the immunophenotyping data with the US
reference range data provided by Becton-Dickinson showed good
agreement with the North American population although the
upper limit of the reference range for all T cell absolute counts was
higher in the North American population (Table 4). The reference
range for the US population was also wider for all lymphocyte
subsets, except NK cells, although the US sample size was
considerably smaller (N=164), which may account for the wider
range. The reference ranges for CD4 T cell numbers and
Table 1. Lymphocyte subset reference ranges (median and
95th-percentile) derived from HIV-seronegative adults in
Kericho, Kenya.
Parameter Male Female All participants
(N=848) (N=445) (N=1293)
CD3+ T cells/ml
a 1293 (711–2351) 1,660 (851–2742) 1415 (744–2634)
CD3+ T cells %
a 72 (54–83) 74 (57–84) 73 (55–84)
CD4+ T cells/ml
a 744 (407–1340) 982 (483–1651) 810 (421–1550)
CD4+ T cells %
a 41 (30–55) 44 (32–56) 42 (30–55)
CD8+ T cells/ml
a 454 (195–1046) 549 (225–1097) 486 (210–1081)
CD8+ T cells % 26 (14–40) 25 (15–38) 26 (14–39)
CD4:CD8 ratio
a 1.6 (0.8–3.3) 1.7 (0.9–3.3) 1.7 (0.9–3.3)
B-lymphocytes /ml
a 218 (86–551) 295 (122–716) 244 (93–627)
B lymphocytes %
a 12 (6–21) 13 (7–23) 12 (6–22)
NK cells /ml 252 (82–752) 255 (84–716) 253 (83–739)
NK cells %
a 14 (5–30) 11 (4–27) 13 (4–30)
a: P value of ,0.05 using the Wilcoxon rank test.
doi:10.1371/journal.pone.0003327.t001
Table 2. Hematology reference ranges (median and 95th-percentile) derived from HIV-seronegative adults in Kericho, Kenya.
Parameter Male Female All participants
(N=1020) (N=521) (N=1541)
Hemoglobin (g/dL)
a 9.9 (8.3–11.3) 8.44 (5.9–10.0) 9.5 (6.7–11.1)
Hematocrit (%)
a 47 (40–50) 40 (30–50) 45 (30–50)
Erythrocytes (10/
12L)
a 5.3 (4.4–6.3) 4.8 (3.7–5.6) 5.1 (4.0–6.2)
Platelets (10/
9L)
a 218 (115–366) 251 (124–444) 226 (120–411)
WBC (10
9/liter)
a 4.3 (2.7–7.5) 4.9 (3.0–9.1) 4.4 (2.8–8.2)
MCH (pg)
a 30.1 (23.3–33.8) 28.9 (21.3–33.0) 29.8 (22.4–33.5)
MCV (fl)
a 88.0 (71.4–98.2) 84.9 (66.0–95.7) 87.0 (68.8–97.2)
MCHC (g/L)
a 342 (324–353) 339 (322–352) 341 (322–353)
Neutrophils (10/
9L)
a 1780 (871–4324) 1960 (987–5558) 1850 (914–4715)
Neutrophils (%) 42 (20–70) 42 (20–70) 42 (20–60)
Lymphocytes (10/
9L)
a 1860 (1120–3160) 2160 (1290–3957) 1950 (1140–3454)
Lymphocytes (%) 45 (20–60) 45 (20–60) 45 (20–60)
Monocytes (10/
9L)
a 280 (130–585) 300 (160–640) 290 (130–600)
Monocytes (%)
a 7 (3–12) 6 (3–11) 7 (3–11)
Eosinophils (10/
9L)
a 150 (30–1080) 170 (34–1218) 160 (30–1139)
Eosinophils (%) 4 (1–20) 4 (1–20) 4 (1–20)
Basophils (10/
9L) 30 (10–90) 30 (10–70) 30 (10–80)
Basophils (%)
a 0 (0–2) 0 (0–1) 0 (0–2)
a: P value of ,0.05 using the Wilcoxon rank test.
doi:10.1371/journal.pone.0003327.t002
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from Tanzania and Ethiopia [11,24]. The CD4:CD8 reference
range ratio was very similar for the Kenyan and Tanzanian
participants, but the lower limit was at least 2-fold higher than that
seen for Ethiopians [11,24].
The Kenyan hematology parameters showed marked differenc-
es for hemoglobin, leukocyte counts and eosinophils compared
with a North American group (Table 5) [22]. The lower and upper
reference ranges for hemoglobin and eosinophils, respectively,
were 2 times lower for the former in women and 2.5 times higher
for the latter compared to the US group [22].
The Kenyan reference ranges for clinical chemistry analytes
showed higher enzyme and electrolyte levels compared to North
Americans [22]. The Kericho data are more comparable to the
Mbeya, Tanzania data [24] than the US reference ranges
(Table 6). The reference range for blood urea nitrogen was much
lower than that for the US group, with the upper limit for the
latter being 1.5-fold more than that of Kericho.
Discussion
Our data collection method was in accordance with the rigorous
CLSI guidelines for determining laboratory reference ranges,
which recommends a minimum of 153 subjects for a 95
th
percentile clinical reference range determination with 95%
confidence [17].
The Kenyan group CD4 reference range is also comparable to
that measured in Nigeria (309–1327 cells/ml) [3] and a study in
Dar es Salaam (405–1500 cells/ml) [15], despite differences in
assay methodologies. The study conducted in Mbeya, Tanzania
was performed in a similar rural population and identical
methodology to our study but showed a narrower and lower
reference range (406–1392 cells/ml) [24]. As seen with most
previous studies, the CD4 median absolute count was higher in
women compared to men [3,5,8,15,16,24,31]. The CD4 reference
range in Kenyan women is comparable to that of African-
American women in the USA. A recent study of 515 African-
American women using two-color flow cytometry reported a mean
CD4 cell count of 1055 cells/ml [32].
Table 3. Clinical Chemistry reference ranges (median and 95th-percentile) derived from HIV-seronegative adults in Kericho, Kenya.
ANALYTE N Male N Female N All Participants
Enzymes
ALT (U/L)
a 1020 22.3 (10.8–53.9) 521 16.8 (8.6–47.0) 1541 20.2 (9.6–52.0)
AST (U/L)
a 1016 23.9 (14.9–45.3) 517 19.1 (13.1–38.1) 1533 22.2 (13.8–42.3)
Amylase (U/L)
a 792 85.1 (40.0–171.3) 413 78.6 (36.0–147.8) 1205 82.4 (38.3–163.0)
Lactate dehydrogenase (U/L)
a 820 174 (124–259) 420 181 (131.5–295.4) 1240 176 (126.0–263.9)
Serum Proteins
Albumin (g/L)
a 1020 42.9 (36.9–48.5) 521 41.7 (34.4–47.5) 1541 42.5 (35.8–48.1)
Metabolism
Bilirubin, total (mmol/L)
a 1020 12.2 (5.6–41.9) 521 9.6 (4.4–26.8) 1541 11.2 (4.9–39.9)
Bilirubin, direct (mmol/l)
a 1020 3.1 (1.3–9.5) 521 2.4 (0.8–6.7) 1541 2.8 (1.1–8.8)
Glucose (mmol/L) 1020 4.1 (3.0–5.6) 521 4.0 (3.2–5.7) 1541 4.1 (3.1–5.7)
Cholesterol (mmol/L)
a 996 3.8 (2.5–5.5) 512 3.9 (2.6–5.9) 1508 3.8 (2.6–5.7)
Triglycerides (mmol/L)
a 974 0.9 (0.4–2.7) 503 0.8 (0.4–2.5) 1477 0.9 (0.4–2.6)
Kidney Function
Creatinine (mmol/L)
a 1019 77 (62–106) 521 66 (51–91) 1540 74 (55–102)
Urea nitrogen (mmol/L)
a 1020 2.8 (1.5–4.6) 521 2.5 (1.4–4.6) 1541 2.7 (1.4–4.6)
Electrolytes
Sodium (mmol/L) 1020 146.5 (141.8–152.1) 521 146.5 (140.3–155.3) 1541 146.5 (141.4–152.5)
Potassium (mmol/L)
a 1017 4.6 (3.9–5.8) 518 4.5 (3.8–5.8) 1535 4.6 (3.9–5.8)
Chloride (mmol/L)
a 1020 105.0 (100.4–110.8) 521 106.9 (101.1–113.4) 1541 105.6 (100.5–111.7)
Carbon dioxide (mmol/L)
a 1020 23.5 (18.9–29.0) 521 21.6 (16.8–26.9) 1541 22.9 (17.7–28.5)
a: P value of ,0.05 using the Wilcoxon rank test.
doi:10.1371/journal.pone.0003327.t003
Table 4. Comparison of Lymphocyte Reference Ranges from
Kericho, Kenya with those from other countries.
Parameter Kericho Tanzania[24] Ethiopia[11] USA
a
CD3+ T cells/ml 744–2634 683–2106 854–2556 723–2737
CD3+ T cells % 55–84 52–80 NA 56–86
CD4+ T cells/ml 421–1550 406–1392 366–1235 404–1612
CD4+ T cells % 30–55 27–52 NA 33–58
CD8+ T cells/ml 210–1081 188–990 311–1618 220–1129
CD8+ T cells % 14–39 13–40 NA 13–39
CD4:CD8 ratio 0.9–3.3 0.8–3.2 0.4–2.4 NA
B-lymphocytes /ml 93–627 109–637 51–419 80–616
B lymphocytes % 6–22 6–24 NA 5–22
NK cells /ml 83–739 123–801 75–581 84–724
NK cells % 4–30 6–34 NA 5–26
a: Reference ranges provided by Becton-Dickinson with the MultiTEST IMK Kit
Reagent package (12/2000;23-3602-02).
b:NA-Not Available.
doi:10.1371/journal.pone.0003327.t004
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parameters, and the trend agreed with most published studies
[8,10,24]. The finding of higher values for hemoglobin, hematocrit
and erythrocytes in males compared to females may be partly due
to the influence of androgen on erythropoiesis, menstrual loss and
parity. Compared to other African sites, such as Akaki, a high-
altitude (2100 m) site in Ethiopia, and Mbeya, Tanzania, our
reference ranges were similar, with the exception of hemoglobin,
which was much lower in the Kenyan group [11,24]. One major
difference in our rural population compared to those from
industrialized nations was the higher eosinophil count. Eosino-
philia may be related to parasitemia, as our medical examination
did not include intestinal helminthes, which is a limitation of this
study. A stool parasitologic survey performed in 2002 within
100 km of Kericho, reported a prevalence of Ascaris lumbricoides,
hookworm and Trichuris trichuri of 10, 4 and 0.1%, respectively, but
no other parasites were assessed [33].
The two surprising findings in this study were the reference
ranges for hemoglobin and the differential for neutrophils. It could
be argued that the difference between our hemoglobin data and
that from Ethiopia might be due to diet and methodology. The
major food of the people of the Akaki region has a very high iron
content [11]. Additionally, Kericho is about 400 m–600 m higher
than the Tanzanian study site, therefore, the hemoglobin levels
should be higher than Mbeya [34]. Interestingly, while iron was
not directly measured in this cohort, 26% of women and 9% of
men had an MCV of ,80 fl, which is an indirect marker of iron
deficiency. The difference in the neutrophil % reference range for
this study and that from Mbeya may be the result of differences in
pathogen exposure and/or population genetics, or diet. It has been
argued that benign ethnic neutropenia should be considered a
variation of normal as it does not appear to incur a clinical
disadvantage [35].
White blood cell and platelet counts and hemoglobin levels are
usedasinclusionand/orexclusioncriteriainPhaseI/IIvaccinetrials.
TheDivisionofAIDS(DAIDS)hashematologicalcriteriaforgrading
the severity of potential vaccine related adverse events (AE): http://
www3.niaid.nih.gov/research/resources/DMIDClinRsrch/toxtables.
htm. The lower limit of the Kenyan group’s reference range
neutrophil count would be classified as a moderate adverse event
(range 750–999610
9 /L) and the lower limit of the hemoglobin
reference range for the group would have been graded as a severe
adverse event (range 6.5–7.4 g/dL). However, stratifying hemoglo-
bin by gender shows that the lower limit for males would have been
graded as a moderate AE, but that for women would have been
classified as potentially life-threatening. A hematologic reference
Table 5. Hematology reference ranges from Kericho, Kenya compared to other sources in Africa and the United States of America.
Parameter Kenya Tanzania[24] Ethiopia[11] USA[22]
Hemoglobin (g/dL)
All 6.7–11.1 11.7–17.2 NA
a NA
Male 8.3–11.3 13.7–17.7 13.9–18.3 13.5–17.5
Female 5.9–10.0 11.1–15.7 12.2–16.6 12.0–16.0
Hematocrit %
All 35.0–55.0 36.0–53.0 NA NA
Male 40.0–50.0 40.2–53.7 41.6–55.1 41.0–53.0
Female 30.0–50.0 36.2–46.8 35.3–48.8 36.0–46.0
RBC (610
12/L)
All 4.0–6.2 4.0–6.1 NA NA
Male 4.4–6.3 4.4–6.3 4.3–5.9 4.5–5.9
Female 3.7–5.6 3.8–5.6 3.7–5.2 4.0–5.2
Platelets (610
9/L) 120–411 150–395 NA 150–350
WBC (61,000) 2.8–8.2 3.0–7.9 3.0–10.2 4.5–11.0
MCH (pg) 22.4–33.5 23.6–33.1 NA 26.0–34.0
MCV (fl) 68.8–97.2 77.6–98.1 NA 80.0–100.0
MCHC (g/dl) 322–353 306–349 NA 310–370
Neutrophils (610
9/L) 0.9–4.7 1.1–4.7 NA NA
Neutrophils % 20–60 32–69 31–78 40–70
Lymphocytes (610
9/L) 1.1–3.5 1.1–3.0 NA NA
Lymphocytes % 20–60 21–57 17–59 22–44
Monocytes (610
9/L) 0.1–0.6 NA NA NA
Monocytes % 3–11 NA 3–10 4–11
Eosinophils (610
9/L) 0.03–1.1 NA NA NA
Eosinophils % 1–20 NA NA 0–8
Abs Basophils (610
9/L) 0.01–0.08 NA NA NA
Basophils % 0–2 NA NA 0–3
a: NA-Not Available.
doi:10.1371/journal.pone.0003327.t005
Reference Ranges for Kenya
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(1175 m) in Uganda, using identical instrumentation to our study,
reported a lower reference range for hemoglobin of 11.1 g/dL and
10.1 g/dL for men and women respectively, based on the lower 5
th
percentile and not the 2.5
th percentile of the current study [8]. It is
difficult to establish why our reference range values for hemoglobin
were so low compared to other African sites using identical
methodology. It is unlikely to be due to malaria being under-
diagnosed, as the study team was proficient in malaria diagnostics
by blood smear. One report from a nearby highland community in
Kenya reported a prevalence of Plasmodium falciparum of 5%, which
was marginally higher than our study [33]. The lower reference
range limit for platelet count in this study would have been a mild
adverse event (range 100–125610
9 /L) using the DAIDS AE tables.
Sickle cell anemia and malnutrition may have also played a role in
the low values for hemoglobin. However a sickle cell trait survey
conducted in the region demonstrated a frequency of 2.5% in tribes
representing 52% of the group [28,36]
The clinical chemistry reference range data from Kericho
compared to the US are similar for most parameters, with the
exception of urea nitrogen, which was considerably lower in the
Kenyan study. Interestingly, urea nitrogen for the Tanzanian
study using the identical methodology was in better agreement
with this study than the US data [22]. Similarly, the upper
reference value for total bilirubin in the Kenyan group, as seen
with the Tanzanian study, was over 2-fold that of the US data
[22,24]. The glucose measurement in the current study was for
non-fasting glucose, unlike the US data [22], and the lower limit of
the reference range would have been considered a mild serious
adverse event by the DAIDS toxicity tables (range: 3.1–3.6 mmol/
L) It should be stressed that neither the methodology nor the
sample size used for the US reference range data is known.
This study provides the first lymphocyte, hematology and
clinical chemsitry reference range data for Kericho, Kenya, and to
date is the largest cohort from which reference range data has
been collected in Africa. While our data showed similarities with
industrialized countries, there were striking differences, particu-
larly for hematology and clinical chemistry. WHO has designated
hemoglobin and glucose measurement as essential laboratory
services for sub-Saharan Africa [37]. The reference range data
generated from the Kericho study showed that these two
parameters, particularly the former, are widely different to those
of the US. Using recent data from the US which defines anemia in
African-American men and women as hemoglobin ,12.9 g/dL
and ,11.5 g/dL, respectively, the entire Kericho study popula-
tion would have been classified as anemic [38]. Our study has
shown that strict adherence to reference ranges developed in
industrialized countries for HIV vaccine and/or treatment trials
could exclude many healthy Kenyans from participating in these
studies. Similarly, the use of ‘‘Western’’ reference ranges for
clinical management could lead to unnecessary treatment. Our
study not only allowed definition of reference ranges for a rural
area in Kenya, but also enhanced local laboratory capacity as it
was conducted under Good Clinical Laboratory Practices
guidelines [39] thus preparing the site for clinical trials with
potential product licensure by the US FDA.
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